Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas' Brazilian Affiliate Starts Operation
June 28, 2010
- FDA Orders Eisai, Sepracor to Stop Using Some Promotional Materials
June 28, 2010
- Kansai Bio-Promotion Allies with Flanders Bio
June 28, 2010
- ACRONET Invests in Chinese CRO NANDACRO
June 28, 2010
- CMIC Decides to Develop Sodium Phenylbutyrate
June 28, 2010
- NCCHD Considers Gene Therapy for Chronic Granuloma
June 28, 2010
- FTC Warns Nakazawa Ujike for Possible Anti-Monopoly Act Infringements
June 28, 2010
- Interim Analysis Confirms Safety of Tykerb in PIII for Stomach Cancer
June 28, 2010
- Merck Serono to Launch More Than 6 Products in 2012 Onward
June 28, 2010
- MCI to Launch New Detailing Tool Using iPad in July
June 28, 2010
- Cabazitaxel Increases OS in Prostate Cancer Patients
June 28, 2010
- Novo Launches Japan's 1st GLP-1 Agonist Victoza
June 28, 2010
- Sutent Fails to Show Efficacy for Breast Cancer in All 4 of the PIII Trials
June 28, 2010
- Korosho's Panel Begins Discussions for Early Diagnosis of COPD
June 28, 2010
- Hisamitsu, Kyowa Kirin Launch Fentos Tape for Relief of Cancer Pain
June 28, 2010
- Maintenance Therapy with Rituximab Halves Risk of Recurrent Lymphoma
June 28, 2010
- Takeda Launches 3 New Products Aiming at Combined Sales of ¥10 Bil. in 1st Year
June 28, 2010
- Speed Is Key to Success of sanofi-aventis Nichi-Iko: Dr Chocat
June 28, 2010
- Denosumab Effective for Bone Metastasis Following Prostate Cancer
June 28, 2010
- Daiichi Sankyo to Develop Vaccine Business in Japan and Emerging Markets
June 28, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…